Mintage Journal of Pharmaceutical and Medical Sciences (ISSN: 2320-3315)

Author(s): KOTRASEETHA RAM1*,PERAVALIJB2,ANMOL KUMAR1, KRS SAMBASIVA RAO1,KK PULICHERLA

Every year most of the deaths were leaded by cardio and cerebrovascular disorders around the globe. The use of first or second generation thrombolytics may rise several side  effects  like  bleeding  in  biological  system  at  the  time  of  treatment.  New generation  thrombolytics  plays  an  important  role  in  the  treatment  of  thromboembolic  disorders which leads to the death. An ideal fibrin specific plasminogen activator, staphylokinase converts a precursor, plasminogen toactive enzyme, plasmin to dissolve the blood clot during thrombolytic therapy and italso capable to destroy the normal components of haemostatic system which leads to life threatening consequence and also death. Out of four  different  thrombolytics  which  are  available  in  market  like alteplase,  reteplase,  streptokinase  and  tenecteplase,  streptokinase  was  widely  used  drug  because  of  its  low cost.But, to overcome the hurdles like bleeding and reocculsion efforts have been made to construct the more potent staphylokinasedevoid of risk. In this review, progressive development on staphylokinase has been discussed.